skip to content

Clinical Trials

MainTitle

Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

This study has been completed
Sponsor
Palo Alto Medical Foundation


Information provided by (Responsible Party)
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier
NCT00002064

First received: November 2, 1999
Last updated: June 23, 2005
Last Verified: June 1989
History of Changes
Purpose

Purpose

To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.

Condition Intervention
Toxoplasmosis, Cerebral
HIV Infections

Drug : Pyrimethamine
Drug : Clindamycin

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Exclusion Criteria
Co-existing Condition:
Patients with the following conditions are excluded:

  • Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal
meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.
Patients with other opportunistic infections or brain diseases are excluded.
Patients with AIDS and cerebral toxoplasmosis.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002064

Locations

United States, California
Palo Alto Med Foundation
Palo Alto, California, United States, 94301

Sponsors and Collaborators

Palo Alto Medical Foundation
More Information

More Information


Responsible Party: Palo Alto Medical Foundation  
ClinicalTrials.gov Identifier: NCT00002064   History of Changes  
Other Study ID Numbers: 021A  
Study First Received: November 2, 1999  
Last Updated: June 23, 2005  

Keywords provided by NIH AIDS Clinical Trials Information Service:

Sulfonamides
Toxoplasmosis
AIDS-Related Opportunistic Infections
Pyrimethamine
Drug Therapy, Combination
Encephalitis
Acquired Immunodeficiency Syndrome
Clindamycin

Additional relevant MeSH terms:
HIV Infections
Encephalitis
Toxoplasmosis
Toxoplasmosis, Cerebral
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Pyrimethamine

ClinicalTrials.gov processed this data on October 20, 2017
This information is provided by ClinicalTrials.gov.